FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number: 3235-0								
l	Estimated average burden								
l	hours per response:	0.5							

hours per response:

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Fitzgerald Richard F</u>				2. Issuer Name and Ticker or Trading Symbol Sesen Bio, Inc. [ SESN ]						(Che	ck all application	able)	erson(s) to Issu 10% Ov	vner	
(Last) (First) (Middle) C/O SESEN BIO, INC.					3. Date of Earliest Transaction (Month/Day/Year) 02/21/2019						X Officer (give title Other (specify below)  Chief Financial Officer				
245 FIRST STREET, SUITE 1800  (Street)  CAMBRIDGE MA 02142  (City) (State) (Zip)				4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
Date			. Transact Date Month/Day	Execution Date, Transaction Disposed Of (D) (Instr.		str. 3, 4 and 5	Securities Beneficia Owned For Reported Transacti	5. Amount of Securities Form Beneficially (D) o Owned Following Reported Transaction(s) (Instr. 3 and 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Code	ansaction Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	· V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	<i>3</i>	
Employee Stock Option (Right to Buy)	\$0.8285	02/21/2019		A		178,500		(1)	02/21/2029	Common Stock	178,500	\$0	178,500	D	

## Explanation of Responses:

1. On February 21, 2019, the reporting person was awarded options to purchase 178,500 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date.

## Remarks:

/s/ Richard F. Fitzgerald 02/25/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.